ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

The Role of Checkpoint Inhibitors in the Treatment of Head and Neck Cancer

by Jennifer L.W. Fink • September 18, 2016

  • Tweet
  • Email
Print-Friendly Version
T lymphocyte cells (orange) surrounding a cancer cell.

T lymphocyte cells (orange) surrounding a cancer cell.
© Spencer Sutton / Science Source.COM

This year, the National Institutes of Health estimates that approximately 60,000 Americans will be diagnosed with head and neck cancer. Although survival rates have increased over the last 30 years, the five-year relative survival rate for oral and oropharyngeal cancers is still only approximately 60% percent. Otolaryngologists, surgeons, and medical and radiation oncologists have had little to offer to patients whose disease has progressed despite surgery, chemotherapy, and radiation—until now.

You Might Also Like

  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • Should Surgery Be First-Line Treatment for Head and Neck Cancer?
Explore This Issue
September 2016

In early August 2016, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck Sharp and Dohme Corp.) for use in patients with recurrent or metastatic head and neck squamous cell carcinoma that is refractory to platinum-based chemotherapy. The drug received accelerated approval based on early data from the KEYNOTE-012 trial. Trial participants received 200 mg of pembrolizumab IV every three weeks for 24 months, or until disease progression or they reached intolerable toxicity. The overall objective response rate was 16%, with a complete response rate of 5%. The drug elicited response in both HPV-positive and HPV-negative tumors (24% vs. 16%). Eighty-two percent of those who responded to the medication did not have progression of disease for at least six months. Now, some patients are doing well more than two years out from their initial treatments (J Clin Oncol. 2016;34(suppl; abstr 6011)).

The traditional platform for treating head and neck has been a table with three legs, surgery, radiotherapy, and chemotherapy. Immunotherapy, in essence, brings a fourth leg to the table. —David Brizel, MD

Pembrolizumab is a checkpoint inhibitor, a drug that essentially unmasks tumor cells so the immune system can attack and destroy them. Specifically, pembrolizumab is a PD-L1 inhibitor; it inhibits the interaction of PD-L1, a protein on tumor cells and PD-1, a protein on T-cells. Checkpoint inhibitors “turn off the off switch, which has the net effect of turning the immune system back on,” said David Brizel, MD, Leonard Prosnitz Professor of Radiation Oncology at Duke University in Durham, N.C.

The idea of unleashing the immune system against cancer cells is not new. What is new is the hope that these medications are offering hope to patients who would otherwise have no options. Maura Gillison, MD, PhD, professor of medicine and Jeg Coughlin Chair of Cancer Research at The Ohio State University Comprehensive Cancer Center in Columbus, has seen remission following checkpoint inhibitor treatment in some of her patients.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Head and Neck, Home Slider, Special Report Tagged With: checkpoint inhibitors, head and neck cancer, immunotherapy, treatmentIssue: September 2016

You Might Also Like:

  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • Should Surgery Be First-Line Treatment for Head and Neck Cancer?

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Vertigo in the Elderly: What Does It Mean?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Is the Training and Cost of a Fellowship Worth It? Here’s What Otolaryngologists Say
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Why Virtual Grand Rounds May Be Here to Stay
    • Otolaryngologist Leverages His Love of Pinball into Second Business
    • These New Imaging Advances May Help to Protect Parathyroids
    • Is the Training and Cost of a Fellowship Worth It? Here’s What Otolaryngologists Say
    • Which Otologic Procedures Poses the Greatest Risk of Aerosol Generation?

Polls

Have you used 3D-printed materials in your otolaryngology practice?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.